Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.
Institute of Cancer Research, London, UK; Department of Radiology, Royal Marsden NHS Foundation Trust, London, UK.
Eur Urol. 2016 Jun;69(6):1028-33. doi: 10.1016/j.eururo.2015.10.010. Epub 2015 Oct 21.
In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers.
To determine long-term outcomes with respect to the apparent diffusion coefficient (ADC) derived from diffusion-weighted magnetic resonance imaging (DW-MRI) in a prospective AS cohort. Early results have already been published; we now present findings with long-term follow-up.
DESIGN, SETTING, AND PARTICIPANTS: A subset of patients (n=86) underwent pre-enrolment DW-MRI in a prospective AS study between 2002 and 2006. Inclusion criteria were untreated prostate cancer, clinical T1/T2a/N0M0, Gleason ≤ 3+4, and prostate-specific antigen (PSA) <15 ng/ml. Protocol follow-up was by biopsy at 18-24 mo and then every 24 mo, with regular PSA measurement.
Men underwent baseline DW-MRI in addition to standard sequences. ADC was measured from the index lesion on T2-weighted images. To avoid influencing treatment decisions, DW-MRI sequence results were not available to the AS study investigators.
Baseline ADC was analysed with respect to time to radical treatment (TRT) and time to adverse histology (TAH). Kaplan-Meier analysis and univariate and multivariate regression analyses were performed.
The median follow-up was 9.5 yr (interquartile range 7.9-10.0 yr). On univariate analysis, ADC below the median was associated with shorter TAH (hazard ratio [HR] 2.13, 95% confidence interval [CI] 1.17-3.89; p<0.014) and TRT (HR 2.54, 95% CI 1.49-4.32; p<0.001). Median TRT was 9.3 yr (95% CI 7.0-11.6 yr) for patients with ADC above the median and only 2.4 yr (95% CI 1.5-6.0 yr) for ADC below the median. For TRT, addition of ADC to a multivariate model of baseline variables resulted in a significant improvement in model fit (HR 1.33, 95% CI 1.14-1.54; p<0.001). Receiver operating characteristic analysis for TRT revealed an area under the curve of 0.80 (95% CI 0.70-0.88). The number of variables included in the multivariate model was limited by sample size.
Long-term follow-up for this study provides strong evidence that ADC is a useful marker when selecting patients for AS. Routine DW-MRI is now being evaluated in our ongoing AS study for initial assessment and as an alternative to repeat biopsy.
Before entering a study of close monitoring for the initial management of prostate cancer, patients had a type of magnetic resonance imaging scan that looks at the movement of water within cancers. These scans may help in predicting whether patients should receive close monitoring or whether immediate treatment should be given.
在前列腺癌的主动监测(AS)中,关于与新型成像标志物相关的长期结果的数据很少。
在一项前瞻性 AS 队列中,确定源于扩散加权磁共振成像(DW-MRI)的表观扩散系数(ADC)的长期结果。早期结果已经发表;我们现在介绍具有长期随访的发现。
设计、设置和参与者:在 2002 年至 2006 年期间,一项前瞻性 AS 研究中,一部分患者(n=86)接受了预登记 DW-MRI。纳入标准为未经治疗的前列腺癌、临床 T1/T2a/N0M0、Gleason≤3+4 和前列腺特异性抗原(PSA)<15ng/ml。方案随访是在 18-24 个月时进行活检,然后每 24 个月进行一次,同时定期测量 PSA。
男性除了标准序列外还接受了基线 DW-MRI。ADC 是从 T2 加权图像上的指数病变中测量出来的。为了避免影响治疗决策,DW-MRI 序列结果对 AS 研究人员不可用。
ADC 与根治性治疗(TRT)和不良组织学(TAH)的时间进行了基线分析。进行了 Kaplan-Meier 分析和单变量及多变量回归分析。
中位随访时间为 9.5 年(四分位距 7.9-10.0 年)。在单变量分析中,ADC 低于中位数与较短的 TAH(危险比 [HR] 2.13,95%置信区间 [CI] 1.17-3.89;p<0.014)和 TRT(HR 2.54,95% CI 1.49-4.32;p<0.001)相关。ADC 高于中位数的患者中位 TRT 为 9.3 年(95% CI 7.0-11.6 年),而 ADC 低于中位数的患者仅为 2.4 年(95% CI 1.5-6.0 年)。对于 TRT,将 ADC 添加到基线变量的多变量模型中,显著改善了模型拟合(HR 1.33,95% CI 1.14-1.54;p<0.001)。TRT 的受试者工作特征分析显示曲线下面积为 0.80(95% CI 0.70-0.88)。多变量模型中包含的变量数量受到样本量的限制。
本研究的长期随访提供了有力证据,表明 ADC 是选择 AS 患者的有用标志物。常规 DW-MRI 目前正在我们正在进行的 AS 研究中进行评估,作为重复活检的替代方法。
在参加前列腺癌初始管理的密切监测研究之前,患者接受了一种磁共振成像扫描,该扫描可观察癌症内水的运动。这些扫描可能有助于预测患者是否应该接受密切监测,还是应该立即进行治疗。